NCT07445438Recruiting
Feasibility of a Multi-omics Platform for Hematological Malignancies
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1040 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- Mar 2025
- Primary completion date
- Mar 2030
- Lead sponsor
- Azienda Ospedaliero-Universitaria di Parma
- NCT number
- NCT07445438
What you commit to
- Study type: Interventional
- Planned participants: 1040
- From Mar 2025 to the primary completion date, Mar 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient without a diagnosis of hematological malignancy.
Age
- Age \<2 year old
Who the study is looking for
- Patient aged \> 2 year old
- Retrospective study:
- Patients previously diagnosed with hematological malignancies
- Prospective study:
- Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion).
- Patients with clinical suspicion of R/R onco-hematological disorder, requiring a diagnostic assessment using BM aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc.
- Patients with blastic transformation from a chronic condition or suspect of R/R hematological disease requiring a diagnostic assessment using PB drawn, BM aspirate/biopsy, lymph nodes biopsies, or biopsies of tissues with metastatic involvement, including CSF from lumbar puncture, tissue aspirate, etc.
Age in the registry: 2 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Parma Coordinator of this site? Confirm its status | Parma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.